Hypertrophic cardiomyopathy (HCM) is a very heterogeneous disease. Although primarily caused by mutations in genes encoding sarcomeric proteins, other genes might explain that heterogeneity. Potential candidate genes are GATA transcription factors that regulate the expression of proteins associated with HCM. Exons of GATA2, GATA4, and GATA6 genes were sequenced in 212 patients with unrelated HCM previously analyzed for genes encoding the most frequently mutated sarcomeric proteins. Functional effects of variants were predicted by in silico analyses. 3 potentially pathogenic variants were identified: c.-77G>A in GATA2, p.Ala343Thr (rs370588269) in GATA4, and p.Pro555Ala (rs146243018) in GATA6. Multivariate analyses showed that angina was more frequent in patients carrying sarcomeric and GATA rare variants (55% vs 23.2% in non-carriers of GATA rare variants, OR (95% CI) 7.12 (1.23 to 41.27), p=0.029). Among patients without a known causal mutation, GATA rare variants were associated with a greater maximum posterior wall thickness (16.4±4.4 vs 14.0±3.1 mm in non-carriers, p=0.021). Thus, variants having a putative effect on GATA genes would alter the expression of their target genes and could modify the hypertrophic response. Therefore, although relatively infrequent in patients with HCM, they may represent a novel insight into the molecular mechanisms related to the pathogenesis of HCM.
ElliottPM, AnastasakisA, BorgerMA, . Authors/Task Force members. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J2014;35:2733–79. doi:10.1093/eurheartj/ehu284
2.
ThierfelderL, WatkinsH, MacRaeC, . Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell1994;77:701–12.
3.
ChiuC, BagnallRD, InglesJ, . Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. J Am Coll Cardiol2010;55:1127–35. doi:10.1016/j.jacc.2009.11.016
4.
ChiuC, TeboM, InglesJ, . Genetic screening of calcium regulation genes in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol2007;43:337–43. doi:10.1016/j.yjmcc.2007.06.009
5.
ChenSN, CzernuszewiczG, TanY, . Human molecular genetic and functional studies identify TRIM63, encoding Muscle RING Finger Protein 1, as a novel gene for human hypertrophic cardiomyopathy. Circ Res2012;111:907–19. doi:10.1161/CIRCRESAHA.112.270207
6.
CotoE, PalacinM, MartinM, . Functional polymorphisms in genes of the Angiotensin and Serotonin systems and risk of hypertrophic cardiomyopathy: AT1R as a potential modifier. J Transl Med2010;8:64. doi:10.1186/1479-5876-8-64
7.
FunadaA, KonnoT, FujinoN, . Impact of renin-angiotensin system polymorphisms on development of systolic dysfunction in hypertrophic cardiomyopathy. Evidence from a study of genotyped patients. Circ J2010;74:2674–80. doi:10.1253/circj.CJ-10-0482
8.
HussainS, AsgharM, JavedQ. Resistin gene promoter region polymorphism and the risk of hypertrophic cardiomyopathy in patients. Transl Res2010;155:142–7. doi:10.1016/j.trsl.2009.10.002
9.
Alonso-MontesC, Naves-DiazM, Fernandez-MartinJL, . New polymorphisms in human MEF2C gene as potential modifier of hypertrophic cardiomyopathy. Mol Biol Rep2012;39:8777–85. doi:10.1007/s11033-012-1740-7
10.
MarianAJ. Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol2002;17:242–52. doi:10.1097/01.HCO.0000013803.40803.6A
11.
XuJ, LiZ, RenX, . Investigation of pathogenic genes in Chinese sporadic hypertrophic cardiomyopathy patients by whole exome sequencing. Sci Rep2015;5:16609. doi:10.1038/srep16609
12.
AkazawaH, KomuroI. Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res2003;92:1079–88. doi:10.1161/01.RES.0000072977.86706.23
13.
OrkinSH. GATA-binding transcription factors in hematopoietic cells. Blood1992;80:575–81.
14.
DorfmanDM, WilsonDB, BrunsGA, . Human transcription factor GATA-2. Evidence for regulation of preproendothelin-1 gene expression in endothelial cells. J Biol Chem1992;267:1279–85.
15.
KawanaM, LeeME, QuertermousEE, . Cooperative interaction of GATA-2 and AP1 regulates transcription of the endothelin-1 gene. Mol Cell Biol1995;15:4225–31.
16.
Bupha-IntrT, HaizlipKM, JanssenPM. Role of endothelin in the induction of cardiac hypertrophy in vitro. PLoS ONE2012;7:e43179. doi:10.1371/journal.pone.0043179
17.
MolkentinJD. The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem2000;275:38949–52. doi:10.1074/jbc.R000029200
18.
LiangQ, De WindtLJ, WittSA, . The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem2001;276:30245–53. doi:10.1074/jbc.M102174200
19.
van BerloJH, ElrodJW, van den HoogenhofMM, . The transcription factor GATA-6 regulates pathological cardiac hypertrophy. Circ Res2010;107:1032–40. doi:10.1161/CIRCRESAHA.110.220764
20.
MaronBJ, McKennaWJ, DanielsonGK, ., American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents; European Society of Cardiology Committee for Practice Guidelines. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J2003;24:1965–91. doi:S0195668X03004792
21.
Garcia-CastroM, CotoE, RegueroJR, . [Mutations in sarcomeric genes MYH7, MYBPC3, TNNT2, TNNI3, and TPM1 in patients with hypertrophic cardiomyopathy]. Rev Esp Cardiol2009;62:48–56. doi:13131359
22.
GomezJ, RegueroJR, MorisC, . Mutation analysis of the main hypertrophic cardiomyopathy genes using multiplex amplification and semiconductor next-generation sequencing. Circ J2014;78:2963–71. doi:10.1253/circj.CJ-14-0628
23.
MillerSA, DykesDD, PoleskyHF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res1988;16:1215. doi:10.1093/nar/16.3.1215
24.
RodriguezI, CotoE, RegueroJR, . Role of the CDKN1A/p21, CDKN1C/p57, and CDKN2A/p16 genes in the risk of atherosclerosis and myocardial infarction. Cell Cycle2007;6:620–5. doi:10.4161/cc.6.5.3927
25.
FlanaganSE, PatchAM, EllardS. Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations. Genet Test Mol Biomarkers2010;14:533–7. doi:10.1089/gtmb.2010.0036
26.
BarrettJC, FryB, MallerJ, . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics2005;21:263–5. doi:10.1093/bioinformatics/bth457
27.
GabrielSB, SchaffnerSF, NguyenH, . The structure of haplotype blocks in the human genome. Science2002;296:2225–9. doi:10.1126/science.1069424
28.
KomatiH, MaharsyW, BeauregardJ, . ZFP260 is an inducer of cardiac hypertrophy and a nuclear mediator of endothelin-1 signaling. J Biol Chem2011;286:1508–16. doi:10.1074/jbc.M110.162966
29.
ZhangX, AzharG, ChaiJ, . Cardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factor. Am J Physiol Heart Circ Physiol2001;280:H1782–92.
30.
McKinseyTA, OlsonEN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest2005;115:538–46. doi:10.1172/JCI24144
XuL, ZhaoL, YuanF, . GATA6 loss-of-function mutations contribute to familial dilated cardiomyopathy. Int J Mol Med2014;34:1315–22. doi:10.3892/ijmm.2014.1896
33.
AbecasisGR, AutonA, BrooksLD, . An integrated map of genetic variation from 1,092 human genomes. Nature2012;491:56–65. doi:10.1038/nature11632
34.
FischS, GrayS, HeymansS, . Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy. Proc Natl Acad Sci USA2007;104:7074–9. doi:10.1073/pnas.0701981104
35.
BurattiE, BaralleFE. Influence of RNA secondary structure on the pre-mRNA splicing process. Mol Cell Biol2004;24:10505–14. doi:10.1128/MCB.24.24.10505-10514.2004
36.
van BerloJH, ElrodJW, AronowBJ, . Serine 105 phosphorylation of transcription factor GATA4 is necessary for stress-induced cardiac hypertrophy in vivo. Proc Natl Acad Sci USA2011;108:12331–6. doi:10.1073/pnas.1104499108
37.
CharronF, ParadisP, BronchainO, . Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression. Mol Cell Biol1999;19:4355–65. doi:10.1128/MCB.19.6.4355
38.
MorinS, CharronF, RobitailleL, . GATA-dependent recruitment of MEF2 proteins to target promoters. Embo J2000;19:2046–55. doi:10.1093/emboj/19.9.2046
39.
WangJ, SunYM, YangYQ. Mutation spectrum of the GATA4 gene in patients with idiopathic atrial fibrillation. Mol Biol Rep2012;39:8127–35. doi:10.1007/s11033-012-1660-6
40.
PoirierO, NicaudV, McDonaghT, . Polymorphisms of genes of the cardiac calcineurin pathway and cardiac hypertrophy. Eur J Hum Genet2003;11:659–64. doi:10.1038/sj.ejhg.5201023
41.
LavialF, BessonnardS, OhnishiY, . Bmi1 facilitates primitive endoderm formation by stabilizing Gata6 during early mouse development. Genes Dev2012;26:1445–58. doi:10.1101/gad.188193.112
42.
OsoegawaK, ParodiC, MohammedN, . Sequencing candidate genes associated with conotruncal heart defects. Presented at the 63rd Annual Meeting of the American Society of Human Genetics, Boston, MA (Abstract). 2013.
43.
HeinekeJ, Auger-MessierM, XuJ, . Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J Clin Invest2007;117:3198–210. doi:10.1172/JCI32573
44.
LentjesMH, NiessenHE, AkiyamaY, . The emerging role of GATA transcription factors in development and disease. Expert Rev Mol Med2016;18:e3. doi:10.1017/erm.2016.2
45.
WangS, FuC, WangH, . Polymorphisms of the peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene are associated with hypertrophic cardiomyopathy and not with hypertension hypertrophy. Clin Chem Lab Med2007;45:962–7. doi:10.1515/CCLM.2007.189
